5 Fractions of Pelvic SABR With Intra Prostatic SABR

2016-09-22 20:53:25 | BioPortfolio


Stereotactic Ablative Radiation(SABR) 35 Gy in 5 fractions, once weekly to prostate with simultaneous intraprostatic boost to the MR detected nodule up to 50Gy + 25 Gy in 5 fractions, once weekly simultaneously to seminal vesicles (SV's) and pelvic lymph nodes + 6-18 months of ADT


SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Prostate Cancer


Pelvic SABR with intra-prostatic SABR


Not yet recruiting


Sunnybrook Health Sciences Centre

Results (where available)

View Results


Published on BioPortfolio: 2016-09-22T20:53:25-0400

Clinical Trials [4072 Associated Clinical Trials listed on BioPortfolio]

Prostate SABR With Intra-Prostatic SABR Boost

Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodul...

5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up t...

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR +...

SPORT High-Risk Trial Evaluating SABR in Prostate Cancer

The study will examine stereotactic ablative body radiotherapy (SABR), a new technique to deliver radiotherapy to men with prostate cancer. In addition to this, it will look at the effect ...

SABR for T1-2a N1 NSCLC

Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series. Stereo...

PubMed Articles [15977 Associated PubMed Articles listed on BioPortfolio]

Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.

Randomized data assessing the longitudinal quality of life (QoL) impact of SABR in the oligometastatic setting are lacking.

Response evaluation after stereotactic ablative radiotherapy for localized non-small-cell lung cancer - an equipoise of available resource and accuracy.

There is growing evidence supporting the use of stereotactic ablative radiotherapy (SABR) on the treatment of localized stage non-small-cell Lung cancer (NSCLC). Distinctive imaging challenges are pos...

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.

Stereotactic ablative body radiotherapy (SABR) is an emerging noninvasive approach for the treatment of oligometastases. Limited prospective evidence is available in breast cancer.

Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?

Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metas...

Estimating PTV margins in head and neck stereotactic ablative radiation therapy (SABR) through target site analysis of positioning and intrafractional accuracy.

Recurrent and/or previously irradiated head and neck cancers (HNC) are therapeutically challenging and may benefit from high-dose, highly accurate radiation techniques, such as stereotactic ablative r...

Medical and Biotech [MESH] Definitions

A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Tumors or cancer of the PROSTATE.

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

More From BioPortfolio on "5 Fractions of Pelvic SABR With Intra Prostatic SABR"

Quick Search

Relevant Topics

Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Searches Linking to this Trial